OncoDNA: MGI Tech and OncoDNA Join Forces to Offer Laboratories a Streamlined NGS Workflow for Implementing Comprehensive Genomic Profiling Oncodeep Kit in Clinical Practice

MGI announced the collaboration with OncoDNA. The OncoDEEP Kit's comprehensive workflow?encompassing sequencing, secondary analysis, and final interpretation of NGS data (OncoKDM) ?is now fully compatible with MGI sequencers. OncoDNA is committed to making the OncoDEEP Kit's end-to-end solution technology-neutral, opening up new setup possibilities for laboratories. Previously limited to one sequencing technology/platform provider, the OncoDEEP Kit's analysis process now also provides exceptional results and clinical insights, supporting laboratories in performing solid tumor Comprehensive Genomic Profiling using MGI sequencers which utilize the cutting-edge DNBSEQ technology. DNBSEQ platforms advance DNA sequencing by using DNA nanoballs (DNBs) loaded onto a Patterned Array chip. The enhanced accuracy and sensitivity, as along with the reduced amplification bias make the DNBSEQ technology an excellent partner for precision oncology. OncoDEEP Kit CGP panel is the largest and the most complete of the market, composed of probes targeting 638 genes for a final content of 1.8 Mb. It supports the identification of all relevant variants involved in various solid tumor types with genes carefully selected based on their biological and the rapeutical relevance. In addition, specific sequences have been added to cover key regions associated with phenotypes of interest such as Tumor Mutational Burden (TMB), Microsatellite Instability (MSI), Loss Of Heterozygosity (LOH) in Tumor Suppressor Genes (TSGs), introns tilling for genes ALK/ROS1/RET and MET-ex14, sub-telomeric Single Nucleotide Polymorphisms (SNPs) for Homologous Recombination Deficiency (HRD) calculation and promoter of TERT. Results of the OncoDEEP Kit's comprehensive workflow on MGI's DNBSEQ platform were presented during the 36th European Congress of Pathology in Florence (September 7-10).